Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction

International Journal of Cardiology

Volumn 141, Issue 2, 2010, Pages 175-181

  Jeong, Young Hoon ^a   Kim, Won Jang ^b   Park, Duk Woo ^b   Choi, Bong Ryong ^a   Lee, Seung Whan ^b   Kim, Young Hak ^b   Lee, Cheol Whan ^b   Hong, Myeong Ki ^b   Kim, Jae Joong ^b   Park, Seong Wook ^b   Park, Seung Jung ^b  

^a Gyeongsang National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

B type natriuretic peptide; Drug eluting stent; No reflow phenomenon; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PACLITAXEL; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY STENT; CREATININE BLOOD LEVEL; DRUG ELUTING STENT; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGE FACTORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CREATININE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NO-REFLOW PHENOMENON; PATIENT ADMISSION; PATIENT TRANSFER; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE;

EID: 77952238236     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.189     Document Type: Article

References (37)

1. Keeley E.C., and Hillis L.D. Primary PCI for myocardial infarction with ST-segment elevation. N Engl J Med 356 (2007) 47-54
2. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
3. De Luca G., Suryapranata H., Ottervanger J.P., et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109 (2004) 1223-1225
4. De Luca G., Suryapranata H., Ottervanger J.P., et al. Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Int J Cardiol 119 (2007) 306-309
5. Spaulding C., Henry P., Teiger E., et al. TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
6. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
7. Brosh D., Assali A.R., Mager A., et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 99 (2007) 442-445
8. Gasior M., Gierlotka M., Lekston A., et al. Comparison of outcomes of direct stenting versus stenting after balloon predilation in patients with acute myocardial infarction (DIRAMI). Am J Cardiol 100 (2007) 798-805
9. Morishima I., Sone T., Okumura K., et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 36 (2000) 1202-1209
10. Thompson P.L., Meredith I., Amerena J., et al. Pravastatin in Acute Coronary Treatment (PACT) Investigators. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina; the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J 148 (2004) e2
11. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
12. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I findings: TIMI Study Groups. N Engl J Med 312 (1985) 932-936
13. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3 (2006) 499-506
14. van 't Hof A.W., Liem A., Suryapranata H., et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 97 (1998) 2302-2306
15. Manciet L.H., Poole D.C., McDonagh P.F., et al. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am J Physiol 266 (1994) H1541-H1550
16. Ito H., Okamura A., Iwakura K., et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 93 (1996) 1993-1999
17. Simes R.J., Topol E.J., Holmes Jr. D.R., et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 91 (1995) 1923-1928
18. Reffelmann T., and Kloner R.A. The no-reflow phenomenon: a basic mechanism of myocardial ischemic and reperfusion. Basic Res Cardiol 101 (2006) 359-372
19. Kojima S., Sakamoto T., Ishihara M., et al. Japanese Acute Coronary Syndrome Study investigators. The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era. Ann Med 36 (2004) 153-160
20. Iwakura K., Ito H., Ikushima M., et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 41 (2003) 1-7
21. Genda S., Miura T., Miki T., et al. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 40 (2002) 1339-1346
22. Foussas S.G., Zairis M.N., Lyras A.G., et al. Early prognostic usefulness of C-reactive protein added to the thrombolysis in myocardial infarction risk score in acute coronary syndrome. Am J Cardiol 96 (2005) 533-537
23. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
24. Morrow D.A., de Lemos J.A., and Blazing M.A. A to Z Investigators. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 294 (2005) 2866-2871
25. Grabowski M., Filipiak K.J., Karpinski G., et al. Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J 148 (2004) 655-662
26. Hong S.N., Ahn Y., Hwang S.H., et al. Usefulness of preprocedural N-terminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 100 (2007) 631-634
27. Stone G.W., Webb J., Cox D.A., et al. Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 293 (2005) 1063-1072
28. Gick M., Jander N., Bestehorn H.P., et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 112 (2005) 1462-1469
29. Ali A., Cox D., Dib N., et al. AIMI Investigators. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol 48 (2006) 244-252
30. de Lemos J.A., Antman E.M., Gibson C.M., et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 101 (2000) 239-243
31. Giri S., Mitchel J.F., Hirst J.A., et al. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Cardiol 86 (2000) 269-274
32. Claeys M.J., Bosmans J., De Ceuninck M., et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 94 (2004) 9-13
33. Ishibashi F., Saito T., Hokimoto S., et al. Combined revascularization strategy for acute myocardial infarction in patients with intracoronary thrombus: preceding intracoronary thrombolysis and subsequent mechanical angioplasty. Jpn Circ J 65 (2001) 251-256
34. Svilaas T., Vlaar P.J., van der Horst I.C., et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358 (2008) 557-567
35. Vlaar P.J., Svilaas T., van der Horst I.C., et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 371 (2008) 1915-1920
36. Tomai F., Ribichini F., Ghini A.S., et al. Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. Eur Heart J 26 (2005) 2099-2105
37. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150